Examples of BI Compound in a sentence
Any such Product (containing a Collaboration Compound and/or a BI Compound that has been selected as a Development Candidate) that is thereby terminated shall be referred to as a “Terminated Product.” If BI terminates the entire Agreement for any reason, then all Potential Development Candidates, Development Candidates and Collaboration Compounds shall be deemed Terminated Products.
It is the intention of this Research Collaboration to move a minimum of one (1) Collaboration Compound or BI Compound into Development at the earliest opportunity.
During the Screening Term, each party shall promptly provide the other party with information and results generated from the Screening Program (the "Exchange Information"), and, without limiting the generality of the foregoing, PPI shall promptly provide BI with SAR Information to the extent reasonably necessary to facilitate BI's selection of a BI Compound for Development; provided, however, that PPI shall not be required to provide BI with any clinical data relating to any PPI Compound.
In order that PPI may realize the benefits of this Section 3.5.1, (i) BI shall promptly provide PPI with such information as PPI may reasonably require and request with respect to each Designated BI Compound if BI has not taken either of the actions referred to in clause (i) of the first sentence of this Section 3.5.1 within the time period specified in such clause and (ii) BI shall promptly notify PPI in writing after becoming aware of the occurrence of an Abandonment Date.
In the event that BI is entitled to terminate this Agreement pursuant to Section 10.1.5, BI may terminate this Agreement, in which case all licenses and rights granted to BI shall terminate, except to the extent PPI otherwise determines and advises BI in writing, and BI will immediately cease Development of any BI Compound.
In the event BI achieves a Development or regulatory milestone specified below with respect to a Collaboration Compound or BI Compound, BI shall promptly, but in no event more than ten (10) days after the achievement of each such milestone, notify Vitae in writing of the achievement of such milestone.
It is understood that BI will have no right to, and BI agrees that it will not, develop, manufacture or have manufactured, use, sell or have sold any BI Compound or BI Product for use as a diagnostic, except as and to the extent that such BI Compound or BI Product is required as a diagnostic in order for BI to commercialize a BI Compound, and for BI to sell the corresponding BI Product, as a prophylactic or therapeutic.
In the event BI achieves a Development or regulatory milestone specified below with respect to a Collaboration Compound or BI Compound, BI shall promptly, but in no event more than ****after the achievement of each such milestone, notify Vitae in writing of the achievement of such milestone.
Further, BI shall not use such information if such use will provide a competitive advantage to a Product, Collaboration Compound or BI Compound vis-à-vis one of Vitae’s Non-Core 11β HSD-1 Inhibitors.
In addition, Forma shall have the right to ask BI to negotiate in good faith a royalty-bearing (at the royalty rate set forth in Section 12.6(b)(iv)(1)), worldwide license of the scope described immediately above under the BI Target Technology necessary or reasonably useful to develop, manufacture and commercialize certain Collaboration Compounds from the BI Compound Libraries related to this Collaboration Project.